Retatrutide vs Tirzepatide vs Semaglutide: Research Comparison

The three compounds differ in receptor targeting: semaglutide is a selective GLP-1 receptor agonist, tirzepatide is a dual GLP-1/GIP agonist, and retatrutide is a triple GLP-1/GIP/glucagon agonist. Each step adds one receptor, which creates a distinct research context for each compound.

How do the three receptor profiles compare?

Semaglutide acts at one receptor, tirzepatide at two and retatrutide at three.

How do they differ in structure and research use?

Each compound has its own structure and research context.

• •Semaglutide: a selective GLP-1 receptor agonist, built as a modified GLP-1 analogue with a fatty acid chain (C18 diacid). Its single-receptor profile is well characterised.
• •Tirzepatide: a synthetic peptide carrying both GLP-1 and GIP activity. Receptor pharmacology work describes it as an imbalanced and biased dual GIP and GLP-1 receptor agonist.
• •Retatrutide: LY3437943 (CAS 2381089-83-2), a novel triagonist peptide that adds glucagon receptor agonism to the GLP-1/GIP profile. Triple-receptor research is still emerging, and the glucagon component adds complexity to interpretation.

All three compound classes are available for in-vitro research from Peptide Labs. See the Retatrutide 20mg page, or the Retatrutide Bundle for multi-vial pricing.

Research use only

All comparisons draw on published research literature and are for educational purposes only. Products are supplied strictly for in-vitro laboratory and research use, not for human or animal use, and nothing here is medical advice.

Sources

• •Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI insight, 2020.